Reducing in-stent restenosis: Therapeutic manipulation of miRNA in vascular remodeling and inflammation

Journal of the American College of Cardiology

Volumn 65, Issue 21, 2015, Pages 2314-2327

  McDonald, Robert A ^a   Halliday, Crawford A ^a   Miller, Ashley M ^a   Diver, Louise A ^a   Dakin, Rachel S ^a   Montgomery, Jennifer ^a   McBride, Martin W ^a   Kennedy, Simon ^a   McClure, John D ^a   Robertson, Keith E ^a   Douglas, Gillian ^b   Channon, Keith M ^b   Oldroyd, Keith G ^c   Baker, Andrew H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

late stent thrombosis; miRNA stem loop; neointima; smooth muscle cell

Indexed keywords

MICRORNA; PROTEIN MIR 21; SMALL UNTRANSLATED RNA; STAINLESS STEEL; UNCLASSIFIED DRUG; MIRN-21 MICRORNA, MOUSE;

ANGIOPLASTY CATHETER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARE METAL STENT; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG ELUTING STENT; IN VITRO STUDY; IN-STENT RESTENOSIS; MACROPHAGE; MALE; MOUSE; NEOINTIMA; NONHUMAN; PIG; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; RISK REDUCTION; SMOOTH MUSCLE FIBER; VASCULAR REMODELING; VASCULITIS; ANIMAL; BLOOD VESSEL INJURY; CORONARY RESTENOSIS; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; INFLAMMATION; MALE; MICE, KNOCKOUT; MICRORNAS; SWINE; VASCULAR REMODELING; VASCULAR SYSTEM INJURIES;

EID: 84930019740     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.03.549     Document Type: Article

References (34)

1. P.W. Serruys, P. de Jaegere, and F. Kiemeneij A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group N Engl J Med 331 1994 489 495
2. B. De Bruyne, N.H. Pijls, and B. Kalesan Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease N Engl J Med 367 2012 991 1001
3. H.R. Andersen, T.T. Nielsen, and K. Rasmussen A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction N Engl J Med 349 2003 733 742
4. P.W. Serruys, M.J. Kutryk, and A.T. Ong Coronary-artery stents N Engl J Med 354 2006 483 495
5. A.A. Bavry, and D.L. Bhatt Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis Lancet 371 2008 2134 2143
6. E.P. McFadden, E. Stabile, and E. Regar Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy Lancet 364 2004 1519 1521
7. M. Joner, A.V. Finn, and A. Farb Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202
8. S. Nishio, K. Kosuga, and K. Igaki Long-term (>10 years) clinical outcomes of first-in-man biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents Circulation 125 2012 2343 2353
9. A. Mattesini, G.G. Secco, and G. Dall'Ara ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance J Am Coll Cardiol Intv 7 2014 741 750
10. A. Zampetaki, and M. Mayr MicroRNAs in vascular and metabolic disease Circ Res 110 2012 508 522
11. R.A. McDonald, A. Hata, M.R. MacLean, N.W. Morrell, and A.H. Baker MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling Cardiovasc Res 93 2012 594 604
12. V. Ambros The functions of animal microRNAs Nature 431 2004 350 355
13. R.C. Friedman, K.K. Farh, C.B. Burge, and D.P. Bartel Most mammalian mRNAs are conserved targets of microRNAs Genome Res 19 2009 92 105
14. A.B. Aurora, A.I. Mahmoud, and X. Luo MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca(2)(+) overload and cell death J Clin Invest 122 2012 1222 1232
15. C. Bang, S. Batkai, and S. Dangwal Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy J Clin Invest 124 2014 2136 2146
16. M. Boehm, M. Olive, and A.L. True Bone marrow-derived immune cells regulate vascular disease through a p27(Kip1)-dependent mechanism J Clin Invest 114 2004 419 426
17. J.E. Rectenwald, L.L. Moldawer, T.S. Huber, J.M. Seeger, and C.K. Ozaki Direct evidence for cytokine involvement in neointimal hyperplasia Circulation 102 2000 1697 1702
18. J. Chamberlain, D. Evans, and A. King Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice Am J Pathol 168 2006 1396 1403
19. L. Wang, L.Q. He, and R. Zhang Regulation of T lymphocyte activation by microRNA-21 Mol Immunol 59 2014 163 171
20. K. Smigielska-Czepiel, A. van den Berg, and P. Jellema Dual role of miR-21 in CD4+ T-cells: activation-induced miR-21 supports survival of memory T-cells and regulates CCR7 expression in naive T-cells PloS One 8 2013 e76217
21. Q. Ruan, P. Wang, and T. Wang MicroRNA-21 regulates T-cell apoptosis by directly targeting the tumor suppressor gene Tipe2 Cell Death Dis 5 2014 e1095
22. R. Virmani, and A. Farb Pathology of in-stent restenosis Curr Opin Lipidol 10 1999 499 506
23. C. Jiang, A.T. Ting, and B. Seed PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 391 1998 82 86
24. N. Marx, U. Schonbeck, M.A. Lazar, P. Libby, and J. Plutzky Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells Circ Res 83 1998 1097 1103
25. H. Shu, B. Wong, and G. Zhou Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells Biochem Bioph Res Co 267 2000 345 349
26. A.R. Collins, W.P. Meehan, and U. Kintscher Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice Arterioscler Thromb Vasc Biol 21 2001 365 371
27. A.C. Li, K.K. Brown, M.J. Silvestre, T.M. Willson, W. Palinski, and C.K. Glass Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice J Clin Invest 106 2000 523 531
28. R. Marzio, E. Jirillo, A. Ransijn, J. Mauel, and S.B. Corradin Expression and function of the early activation antigen CD69 in murine macrophages J Leukocyte Biol 62 1997 349 355
29. A.G. Santis, M.R. Campanero, and J.L. Alonso Tumor necrosis factor-alpha production induced in T lymphocytes through the AIM/CD69 activation pathway Eur J Immunol 22 1992 1253 1259
30. R. Ji, Y. Cheng, and J. Yue MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation Circ Res 100 2007 1579 1588
31. M. Wang, W. Li, and G.Q. Chang MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities Arterioscler Thromb Vasc Biol 31 2011 2044 2053
32. L. Maegdefessel, J. Azuma, and R. Toh MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion Sci Transl Med 4 2012 122ra22
33. R.A. McDonald, K.M. White, and J. Wu miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation Eur Heart J 34 2013 1636 1643
34. X. Liu, Y. Cheng, J. Yang, T.J. Krall, Y. Huo, and C. Zhang An essential role of PDCD4 in vascular smooth muscle cell apoptosis and proliferation: implications for vascular disease Am J Physiol Cell Physiol 298 2010 C1481 C1488